Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Receivables - Other (2016 - 2021)

Myriad Genetics (MYGN) has disclosed Receivables - Other for 12 consecutive years, with $2.4 million as the latest value for Q1 2021.

  • On a quarterly basis, Receivables - Other fell 4.0% to $2.4 million in Q1 2021 year-over-year; TTM through Mar 2021 was $2.4 million, a 4.0% decrease, with the full-year FY2020 number at $2.0 million, changed N/A from a year prior.
  • Receivables - Other was $2.4 million for Q1 2021 at Myriad Genetics, up from $2.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $6.9 million in Q3 2017 to a low of $2.0 million in Q3 2020.
  • A 5-year average of $4.1 million and a median of $4.3 million in 2018 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: surged 72.73% in 2017, then tumbled 58.33% in 2020.
  • Myriad Genetics' Receivables - Other stood at $6.0 million in 2017, then fell by 1.67% to $5.9 million in 2018, then tumbled by 40.68% to $3.5 million in 2019, then plummeted by 42.86% to $2.0 million in 2020, then rose by 20.0% to $2.4 million in 2021.
  • Per Business Quant, the three most recent readings for MYGN's Receivables - Other are $2.4 million (Q1 2021), $2.0 million (Q4 2020), and $2.0 million (Q3 2020).